Skip to main content
About
Company Profile
Management Team
Board of Directors
Science
Overview
CD47
STING
Discovery
Pipeline
Overview
TTI-621
TTI-622
TTI-2341 (EGFR Inhibitor)
Undisclosed Targets
For Patients
Overview
TTI-621-01
TTI-621-02
TTI-622-01
Investors
Contact
Contact Information
Careers
Menu
Investors
Stock Information
Stock Quote & Chart
Historical Price Lookup
Analyst Coverage
Financial Information
SEC Filings
Financial Reports
Corporate Governance
Management Team
Board of Directors
Governance Documents
2019 Annual Meeting
Press Releases
Events & Presentations
Investor Resources
Contact Investor Relations
FAQs
Email Alerts
RSS
Normal
Press Release RSS Feed (opens in new window)
Press Releases
Press release year list
2019
2018
2017
2016
2015
2014
2013
Trillium Therapeutics Reports Second Quarter 2019 Financial Results
August 13, 2019
Trillium Therapeutics Provides Corporate Update
July 24, 2019
Download
PDF format download (opens in new window)
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
July 2, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics Reports First Quarter 2019 Financial Results
May 13, 2019
Download
PDF format download (opens in new window)
Trillium Announces Management and Board Changes and Provides Corporate Update
April 30, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients
April 15, 2019
Download
PDF format download (opens in new window)
Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 11, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics to Present at Investor Conferences in April
April 8, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program
April 2, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019
March 27, 2019
Download
PDF format download (opens in new window)
Trillium Therapeutics Reports Annual Financial and Operating Results
March 11, 2019
Download
PDF format download (opens in new window)
Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
March 8, 2019
Download
PDF format download (opens in new window)
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
February 22, 2019
Download
PDF format download (opens in new window)
Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
February 21, 2019
Download
PDF format download (opens in new window)